Durham-based biotech Humacyte has laid off roughly a quarter of its workforce, a sharp cut the company is pitching as a reset to speed up the commercial push for its lab-grown vascular implant, Symvess, while trimming costs in a tough market.
Local report
The move affects about 45 jobs, roughly 25% of staff, most of them in corporate and commercial roles, according to a report in Triangle Business Journal. The outlet described the shakeup as a commercial reset tied to Symvess’ early rollout, with Humacyte reworking its go-to-market strategy rather than pulling back from the product itself.
What the company told investors
In a May 13 investor update, Humacyte said it reorganized its team, cutting headcount by about 45 employees, or roughly 25%, and trimming expected spending by $14.3 million for the rest of 2026. The company estimated about $0.8 million in one-time severance costs and told investors that the restructuring should free up capital to boost commercialization of Symvess and support late-stage clinical programs, according to a press release from Humacyte.
Early Symvess sales lag
So far, the financial payoff has been modest. Humacyte reported Symvess revenue of $500,000 in the first quarter of 2026, up from $100,000 in the same period a year earlier, but its cost of goods sold still far outpaced sales. That mismatch highlighted the commercial challenge, as summarized by Fierce Biotech, which noted the company plans to lean into more targeted sales efforts and medical education hires rather than a broad commercial blitz.
Regional ripple effects
The layoffs add another data point to a growing pattern across the Triangle’s life science sector, where companies are shifting from research-heavy phases to the harsher math of commercialization. In February, Hoodline chronicled a separate round of cuts, highlighting Merck's Durham job cuts tied to an HPV vaccine slump, underscoring the pressure on even well-known players in the region.
What to watch next
For investors and local health systems, the next key test is in the clinic, not the HR department. Humacyte said it expects to present top-line interim results from its V012 Phase 3 hemodialysis study on June 11 at the Society for Vascular Surgery’s meeting. If the data support a new indication, management plans to file a supplemental BLA later this year. Those milestones are central to expanding Symvess’ clinical footprint and will likely influence how aggressively the company can rehire and spend going forward, according to the investor update from Humacyte.
